AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Molecular Targeting Technologies, Inc. has received a $3.17M grant from the National Cancer Institute to support the development of ¹⁷⁷Lu-EBRGD for non-small cell lung cancer.
Sep 23, 2026•about 2 hours ago
West ChesterBiotechnologyHealth Care
Description
Molecular Targeting Technologies, based in West Chester, PA, has been awarded a $3.17M five-year grant from the National Cancer Institute. The funding will advance the development of an investigational radiopharmaceutical targeting integrin αvβ3 for non-small cell lung cancer. This award will support various activities, including preclinical research and planned clinical studies. The aim is to establish a robust foundation for evaluating ¹⁷⁷Lu-EBRGD in patients.
Company Information
Company
Molecular Targeting Technologies
Location
West Chester, Pennsylvania, United States
About
Molecular Targeting Technologies, Inc. (MTTI) is a private, clinical-stage biotech company developing targeted radiopharmaceuticals (TRP) for rare cancers. MTTI is committed to building value by translating innovative TRP to improve human health.
West ChesterBiotechnologyHealth Care